ChengDu ShengNuo BiotecLtd Past Earnings Performance
Past criteria checks 4/6
ChengDu ShengNuo BiotecLtd has been growing earnings at an average annual rate of 8.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 6.1% per year. ChengDu ShengNuo BiotecLtd's return on equity is 10.1%, and it has net margins of 19.2%.
Key information
8.9%
Earnings growth rate
1.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 6.1% |
| Return on equity | 10.1% |
| Net Margin | 19.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
ChengDu ShengNuo BiotecLtd (SHSE:688117) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 04
ChengDu ShengNuo BiotecLtd (SHSE:688117) Strong Profits May Be Masking Some Underlying Issues
Apr 29Recent updates
ChengDu ShengNuo BiotecLtd (SHSE:688117) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 04ChengDu ShengNuo Biotec Co.,Ltd. (SHSE:688117) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Aug 26A Look At The Fair Value Of ChengDu ShengNuo Biotec Co.,Ltd. (SHSE:688117)
Jun 19ChengDu ShengNuo BiotecLtd (SHSE:688117) Strong Profits May Be Masking Some Underlying Issues
Apr 29There's Reason For Concern Over ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) Massive 27% Price Jump
Mar 04Revenue & Expenses Breakdown
How ChengDu ShengNuo BiotecLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 482 | 92 | 136 | 37 |
| 30 Jun 24 | 460 | 72 | 145 | 40 |
| 31 Mar 24 | 458 | 73 | 159 | 34 |
| 31 Dec 23 | 435 | 70 | 161 | 29 |
| 30 Sep 23 | 427 | 60 | 177 | 25 |
| 30 Jun 23 | 402 | 66 | 169 | 20 |
| 31 Mar 23 | 396 | 64 | 164 | 23 |
| 31 Dec 22 | 396 | 64 | 160 | 23 |
| 30 Sep 22 | 368 | 57 | 146 | 24 |
| 30 Jun 22 | 360 | 56 | 154 | 22 |
| 31 Mar 22 | 374 | 64 | 170 | 14 |
| 31 Dec 21 | 387 | 61 | 192 | 14 |
| 30 Sep 21 | 387 | 61 | 207 | 15 |
| 30 Jun 21 | 397 | 53 | 230 | 19 |
| 31 Mar 21 | 401 | 62 | 227 | 20 |
| 31 Dec 20 | 379 | 60 | 214 | 18 |
| 31 Dec 19 | 327 | 48 | 192 | 11 |
| 31 Dec 18 | 278 | 30 | 143 | 16 |
| 31 Dec 17 | 194 | 34 | 72 | 14 |
Quality Earnings: 688117 has a high level of non-cash earnings.
Growing Profit Margin: 688117's current net profit margins (19.2%) are higher than last year (14.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688117's earnings have grown by 8.9% per year over the past 5 years.
Accelerating Growth: 688117's earnings growth over the past year (53.4%) exceeds its 5-year average (8.9% per year).
Earnings vs Industry: 688117 earnings growth over the past year (53.4%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 688117's Return on Equity (10.1%) is considered low.